HC Wainwright Estimates FibroGen FY2024 Earnings

FibroGen, Inc. (NASDAQ:FGEN) – Investment analysts at HC Wainwright issued their FY2024 earnings estimates for FibroGen in a research note issued on Tuesday, December 17th. HC Wainwright analyst M. Keller anticipates that the biopharmaceutical company will post earnings per share of ($0.74) for the year. HC Wainwright has a “Strong-Buy” rating on the stock. The consensus estimate for FibroGen’s current full-year earnings is ($0.86) per share. HC Wainwright also issued estimates for FibroGen’s Q4 2024 earnings at ($0.08) EPS and FY2025 earnings at ($0.53) EPS.

A number of other equities research analysts have also recently issued reports on the company. William Blair reiterated a “market perform” rating on shares of FibroGen in a research note on Wednesday, November 13th. StockNews.com started coverage on shares of FibroGen in a report on Monday, December 16th. They set a “hold” rating on the stock.

FibroGen Stock Performance

Shares of NASDAQ FGEN opened at $0.40 on Thursday. The stock has a 50 day moving average price of $0.35 and a 200 day moving average price of $0.57. The stock has a market capitalization of $40.31 million, a PE ratio of -0.33 and a beta of 0.82. FibroGen has a 52 week low of $0.18 and a 52 week high of $2.93.

FibroGen (NASDAQ:FGEN) last announced its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, beating the consensus estimate of ($0.38) by $0.21. The company had revenue of $46.33 million during the quarter, compared to the consensus estimate of $34.00 million. During the same quarter in the previous year, the business earned ($0.52) EPS.

Institutional Investors Weigh In On FibroGen

Several hedge funds have recently bought and sold shares of the company. Point72 DIFC Ltd raised its stake in FibroGen by 734.2% in the second quarter. Point72 DIFC Ltd now owns 52,254 shares of the biopharmaceutical company’s stock valued at $47,000 after buying an additional 45,990 shares during the period. Doheny Asset Management CA acquired a new position in shares of FibroGen during the 2nd quarter worth approximately $48,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of FibroGen during the 2nd quarter worth approximately $130,000. Sei Investments Co. raised its stake in FibroGen by 38.4% in the 2nd quarter. Sei Investments Co. now owns 149,342 shares of the biopharmaceutical company’s stock valued at $133,000 after acquiring an additional 41,442 shares during the period. Finally, Squarepoint Ops LLC acquired a new stake in FibroGen during the 2nd quarter valued at $145,000. 72.71% of the stock is currently owned by institutional investors and hedge funds.

FibroGen Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.